C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting …

function getCookieValue(cookieName) {
// Split the cookies into an array
const cookies = document.cookie.split(‘; ‘);

// Loop through the cookies to find the one with the specified name
for (let i = 0; i < cookies.length; i++) {
const cookie = cookies[i];
const [name, value] = cookie.split('=');

// Check if the current cookie matches the desired name
if (name === cookieName) {
// Return the cookie value
return decodeURIComponent(value);
}
}

// If the cookie is not found, return null or handle accordingly
return null;
}

const editionCodeValue = getCookieValue('edition_code');
const loggedInValue = getCookieValue('user_logged_in');

window._ga_cd_params = window._ga_cd_params || {};
window._ga_cd_params["edition"] = editionCodeValue;
window._ga_cd_params["is_user_logged_in"] = (loggedInValue === "1") ? true : (loggedInValue === "0") ? false : REBELMOUSE_BOOTSTRAP_DATA.isUserLoggedIn;

// full_url 1: life-science-investing/biotech-investing
window.__inArticleCount = 0;
window.__userData = JSON.parse(localStorage.getItem("userData"));
window.googletag = window.googletag || {cmd: []};
// working with cookie data
function getCookie(name) {
const value = `; ${document.cookie}`;
const parts = value.split(`; ${name}=`);
if (parts.length === 2) return parts.pop().split(';').shift();
}
googletag.cmd.push(function() {
window.__leader_mapping = googletag.sizeMapping().
addSize([1024, 0], [728, 90]). //desktop
addSize([768, 0], [728, 90]). //tablet
addSize([360, 0], [300, 250]). //mobile
build();
window.__sidebar_mapping = googletag.sizeMapping().
addSize([1024, 0], [300, 600]). //desktop
addSize([768, 0], [300, 600]). //tablet
addSize([360, 0], []). //mobile
build();
window.__sidebar_rest_mapping = googletag.sizeMapping().
addSize([1024, 0], [300, 250]). //desktop
addSize([768, 0], [300, 250]). //tablet
addSize([360, 0], []). //mobile
build();
window.__article_mapping = googletag.sizeMapping().
addSize([1024, 0], [728, 90]). //desktop
addSize([768, 0], [300, 250]). //tablet
addSize([360, 0], [[300, 250],[336,280], [250,250]]). //mobile
build();
window.top_mobile_mapping = googletag.sizeMapping().
addSize([1024, 0], []). //desktop
addSize([768, 0], []). //tablet
addSize([400, 0], [320, 100]). //mobile
build();
window.__floater_mapping = googletag.sizeMapping().
addSize([1024, 0], [720, 540]). //desktop
addSize([768, 0], []). //tablet
addSize([360, 0], []). //mobile
build();
window.__mid_page_mapping = googletag.sizeMapping().
addSize([1024, 0], [728, 90]). //desktop
addSize([768, 0], [728, 90]). //tablet
addSize([360, 0], [300, 250]). //mobile
build();
window.__sticky_mapping = googletag.sizeMapping().
addSize([1024, 0], [728, 90]). //desktop
addSize([768, 0], [728, 90]). //tablet
addSize([360, 0], [320, 50]). //mobile
build();

const __section = ("biotech-investing"=='au' || "biotech-investing"=="world")?'home':"biotech-investing";

const firstArg = window.location.pathname.split('/').filter(Boolean)[0];
const __editioncode = (firstArg=='au' || firstArg=="world")?((firstArg=='au')?'australia':'world'):(getCookie("edition_code")|| 'north_america');

// All Layouts
// TopBar
googletag.defineSlot("/3404235/inn_com_top", [728, 90], "div-gpt-ad-1613765039080-0").defineSizeMapping(window.__leader_mapping).addService(googletag.pubads());

// Sidebar
googletag.defineSlot("/3404235/inn_com_sidebar_top", [300, 600], "inn_sidebar_top").defineSizeMapping(window.__sidebar_mapping).addService(googletag.pubads());
//homepage
googletag.defineSlot('/3404235/inn_com_mid_page', [[300, 250], [728, 90]], 'inn_com_mid_page').defineSizeMapping(window.__mid_page_mapping).addService(googletag.pubads());
// Investor Kit — homepage
googletag.defineSlot('/3404235/inn_com_mid_page_home', [[300, 250], [728, 90]], 'inn_com_mid_page_home').defineSizeMapping(window.__mid_page_mapping).addService(googletag.pubads());

// Sidebar Mid 1 — all pages
googletag.defineSlot("/3404235/inn_com_sidebar_mid_1", [300, 250], "inn_sidebar_mid_1").defineSizeMapping(window.__sidebar_rest_mapping).addService(googletag.pubads());

// Sidebar Mid 2
googletag.defineSlot("/3404235/inn_com_sidebar_mid_2", [300, 250], "inn_sidebar_mid_2").defineSizeMapping(window.__sidebar_rest_mapping).addService(googletag.pubads());

// Sidebar Bottom — all pages
googletag.defineSlot("/3404235/inn_com_sidebar_bot", [300, 250], "inn_sidebar_bot").defineSizeMapping(window.__sidebar_rest_mapping).addService(googletag.pubads());

// Sticky Free Report
googletag.defineSlot("/3404235/inn_com_sticky", [[320, 50], [728, 90]], "inn_sticky").defineSizeMapping(window.__sticky_mapping).addService(googletag.pubads());
googletag.pubads().enableSingleRequest();
googletag.pubads().setTargeting("section", __section)
.setTargeting("tags", ["C4 Therapeutics Inc.", "CCCC", "NASDAQ:CCCC", "~rmsc:rebelmouse-image:29654727", "Life Science Investing"])
.setTargeting("post_id", "2674012864")
.setTargeting("post_basename", "c4-therapeutics-presents-cemsidomide-phase-1-multiple-myeloma-data-supporting-potential-best-in-class-profile-at-the-international-myeloma-society-annual-meeting");
googletag.pubads().setTargeting("edition", __editioncode);
googletag.pubads().setTargeting("loggedin", window.__userData && window.__userData.status === "success" ? "true" : "false")
googletag.enableServices();
});
Connect with us
Information
About UsContact UsCareersPartnerships
Advertise With Us
AuthorsBrowse TopicsEventsDisclaimerPrivacy Policy
Australia

North America

World
LoginInvesting News

NetworkYour trusted source for investing success
North America

Australia

World
My INNVideosCompaniesPress ReleasesPrivate PlacementsSUBSCRIBEReports & GuidesMarket Outlook ReportsInvesting Guides ButtonResource
Precious Metals

Battery Metals

Base Metals
Energy
Critical Metals
TechLife Science Biotech MarketBiotech NewsBiotech Stocks Biotech MarketBiotech NewsBiotech StocksHome>Life Science Investing NewsBiotech Investing>
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

{"customDimensions": {"7":"Investing News Network","13":2674012864,"9":"C4 Therapeutics Inc., CCCC, NASDAQ:CCCC, Life Science Investing","12":"Life Science Investing",